Shenzhen Inno Immune

Shenzhen Inno Immune is a biotechnology company based in Shenzhen, China, specializing in the development of advanced cellular therapies, including T-cell receptor engineered T-cell (TCR-T) and chimeric antigen receptor T-cell (CAR-T) therapies. The company utilizes an AI-driven antigen screening and TCR engineering platform to target solid tumors and hematological malignancies, with a focus on HLA-restricted epitopes prevalent in the Chinese population. Shenzhen Inno Immune has established a strategic partnership with EUDA Health to expand into regenerative medicine and stem cell treatments, utilizing its cGMP facility as a hub for cell processing and cryogenic storage. The company is supported by institutional investors such as HSG Capital Group (formerly Sequoia Capital China) and government funding from the Shenzhen Science and Technology Innovation Bureau. Its lead programs include TCR-T therapies for solid tumors and COVID-19, as well as CAR-T therapies for leukemia.